Opiant Pharmaceuticals (OPNT) Tops Q4 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mailGet Alerts OPNT Hot Sheet
Join SI Premium – FREE
Opiant Pharmaceuticals (NASDAQ: OPNT) reported Q4 EPS of $0.17, $0.18 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $13.8 million versus the consensus estimate of $13.26 million.
For earnings history and earnings-related data on Opiant Pharmaceuticals (OPNT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpaceX (SPCX) PT Raised to $230 at Goldman Sachs ahead of earnings release
- Goldman cuts Carl Zeiss Meditec as ‘valuation disconnected from fundamentals’
- US stocks rise ahead of earnings season starting Thursday
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
